News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Senesco Technologies, Inc. (SNT) Announces Results Of Cohort 3 In SNS01-T Phase 1b/2a Trial



12/9/2013 9:18:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) reported results of cohort 3 in its Phase 1b/2a clinical study of SNS01-T at the 55th American Society of Hematology Annual Meeting in New Orleans. Four heavily pre-treated, relapsed or refractory patients, two with diffuse large B-cell lymphoma (DLBCL) and two with multiple myeloma, who were enrolled in cohort 3 at a dosage of 0.2 mg/Kg, completed treatment. Three of the four patients were evaluable for safety.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES